Search Results

Carmell Corporation announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.

Carmell Corporation, a regenerative care company, announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company.

Carmell Therapeutics Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative medicine company today announced the execution of a definitive agreement and plan of merger (the “Merger Agreement”) with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“Axolotl”).

Carmell Corporation, a regenerative care company announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications.

Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics.

Axolotl Biologix, a biotechnology leader in regenerative medicine, is thrilled that the General Services Administration (GSA) has added the complete line of Axolotl Biologix’s products to the Federal Supply Schedule (FSS).

Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce the launch of Axolotl Shot™, an ambient temperature regenerative fluid preloaded into a syringe for ease of use by physicians.

Axolotl Biologix, an innovative biotechnology leader in regenerative medicine, is proud to announce its Chief Science Officer, Robert Kellar, Ph.D., has been recognized as one of Arizona’s top healthcare leaders.

Axolotl’s DualGraft™ and Axolotl Graft™ products have been assigned the code Q4210.

Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.